CopyMark Law Group
4.9/5
Drawing for COMPLEGENT

USPTO serial 90803650

COMPLEGENT

Reviewed by CopyMark Law Group

Reg. 6915728Status 700Registered
Filing date
Status date
Registration date
Dec 6, 2022
Examiner
MESSICK, TABITHA LEE
Law office
TMEG LAW OFFICE 104

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with COMPLEGENT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bassam N. Ibrahim

Bassam N. Ibrahim BUCHANAN INGERSOLL & ROONEY PC1737 KING STREET, SUITE 500ALEXANDRIA, VA 22314UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
040Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; custom manufacturing, namely, contract refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of custom manufacturing in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of custom manufacturing in the field of host cells; technical consultation in the field of custom manufacturing in the field of host cells; providing technical information in the field of contract manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; technical consultation in the field of manufacturing that consists of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicalsACTIVE—
042Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; Technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cellsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 8, 2023NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Jul 6, 2023COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Jul 3, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 21, 2022ES7RTEAS SECTION 7 REQUEST RECEIVED—
Dec 6, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 6, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 14, 2022EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Oct 20, 2022APETASSIGNED TO PETITION STAFF—
Oct 5, 2022EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Sep 20, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 20, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 31, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 13, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 27, 2022AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jul 27, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 26, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 25, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 25, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 16, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 9, 2022DOCKASSIGNED TO EXAMINER—
Sep 12, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 21, 2021TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jul 21, 2021PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 3, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance